Sunmax Biotechnology Co (4728) Fair Value & Analysis
Healthcare · TW · Market cap 20.4B TWD
Fair value as of: Jul 23, 2026
From 26 valuation models · updated 17 days ago
Share price +0.6% over the past month.
A strong business, but screening 25% overvalued on our models.
What matters now
- A high-quality business (quality 87/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- A fairly wide model range (219.87 TWD to 402.66 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 53.96 TWD – 466.01 TWD · fair‑value band 219.87 TWD – 402.66 TWD · the 389.00 TWD price screens above the 293.16 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Sunmax Biotechnology Co (4728) currently trades at 389.00 TWD, while our model-based Fair Value estimate is 293.16 TWD, implying the stock looks roughly 24.6% overvalued today. The Quality Score stands at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Sunmax Biotechnology Co generated revenue of 2.0B TWD at a net margin of 35.6%. Revenue grew 1.9% year over year. It earns a return on equity of 63.1%. The balance sheet holds a net cash position of 681M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 219.87 TWD (bear case) to 402.66 TWD (bull case); at 389.00 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -25%, 4728 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (443.64 TWD) versus Asset-Based (19.90 TWD). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 85 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine.
Full company description
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sunmax Biotechnology Co reported revenue of 2.0B TWD in FY2025 versus 1.0B TWD in FY2021, a compound +18.3%/yr. Reported net income was 726M TWD in FY2025, compounding +31.1%/yr from FY2021.
4728 screens 25% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Sunmax Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sunmax Biotechnology Co (4728) overvalued or undervalued?
What is the fair value of 4728?
What is the quality score of 4728?
What is the revenue of Sunmax Biotechnology Co (4728)?
What is the net profit margin of 4728?
Does Sunmax Biotechnology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sunmax Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.